Asian Fund for Cancer Research posted the following on LinkedIn:
“Thanks to the long-term support of AFCR’s loyal donors, AFCR-funded scientists have made impressive progress in the fight against cancer.
Outstanding scientific research achievements in 2024 include: the first molecular glue degradation agent. Dr. Zou Lihui researched a new class of small molecule drugs developed through a molecular glue-based targeted protein degradation platform.
The proprietary platform has curated a unique and expanding library of molecular glue compounds, enabling the targeting of previously undruggable targets.
Donate to support cancer research.
Learn more.”